Disclosed is a process of making a nanoparticle comprising an inner core comprising a virus and an outer surface comprising a cellular membrane derived from a cell via extrusion.

Provided are methods for treating a disease using bioengineered enucleated cells. Also provided herein are compositions comprising enucleated cells, wherein the enucleated cells have been loaded with clinically relevant biomolecules.

A monocyte, monocyte derived cell or macrophage infected with an oncolytic herpes simplex virus is disclosed together with uses of such infected cells in the treatment of diseases such as cancer.

This document provides therapeutic compositions, methods of making, and methods of using the described therapeutic compositions that include outer membrane vesicles.

The present development is a transfection reagent prepared by ionic interaction of colostrum powder-derived exosomes and a polycation. The resulting exosome-polycation matrix, or EPM, is entrapped with biologic materials, such as siRNA, mRNA, antisense oligo or plasmid DNA or a plasmid DNA expression construct.

Compositions and methods for treating cancer are provided. In particular, the compositions comprise an anti-neoplastic agent and either an interferon type I agonist or an interferon type II agonist, or a combination of an interferon type I agonist and an interferon type II agonist.

Described herein are systems and methods for a type of paradigm-shift nanoparticles functionalized endothelial optical exosomes for vascular malformation treatment, including Port Wine Stain, using exosomes as a drug delivery vehicle in combination with Near-Infrared-mediated laser therapy.

Provided are engineered B lymphocytes modified to express one or several different types of microRNAs or anti-miRs where in one embodiments the lymphocytes contain multiple copy numbers of nucleic acids encoding the one or several different types of miRs or anti-miRs. Provided are compositions and methods for treating, ameliorating, or preventing a cancer cell, a breast cancer cell or a triple negative breast cancer, or a breast cancer cell that tests negative for estrogen receptors, progesterone receptors, or HER2, comprising or by administering a composition, formulation or pharmaceutical composition comprising a microRNA or anti-miR. Provided are methods for treating an inflammation, a disease, a condition, infection or cancer capable of being treated by modulation or inhibition or expression of an miRNA or anti-miRs by administering to an individual in need thereof a B lymphocyte that secretes a microRNA or anti-miR, or a B lymphocyte supernatant, extracellular vesicle or exosome having a microRNA or anti-miR.

Compositions and methods described in this document make use of macrophage derived engineered vesicles (MEV) having specificity for delivery to a target environment, for use in modifying macrophage phenotype and/or treating a condition. Further disclosed are MEV derived from a specific phenotype encapsulating a therapeutic agent for targeted therapeutic delivery.

The invention relates to red blood cell-derived vesicles comprising encapsulated active agents, their use in therapy and methods of production thereof.